Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus NCFM
- Development stage
- Phase 2
- Lead developer
- DuPont
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Intravaginal
01
Overview
lactobacillus acidophilus NCFM is a specific probiotic bacterial strain of *Lactobacillus acidophilus* developed and studied by Danisco for immunomodulatory and gastrointestinal applications. It has been evaluated as an orally administered single-strain probiotic in human studies including pediatric birch pollen allergy, and has also been studied in atopic dermatitis and other settings, sometimes alongside other probiotic strains. Its therapeutic rationale is microbiome modulation rather than a single defined receptor interaction: after ingestion, the live organism is intended to transiently survive gastrointestinal passage, interact with intestinal epithelial and immune cells, and modulate mucosal and systemic immune responses. Based on the provided sources, this exact asset is best characterized as a strain-specific probiotic live microbial product/dietary supplement rather than a conventional pharmaceutical small molecule or biologic drug.
- Other names
- Lactobacillus acidophilus NCFML. acidophilus NCFM
02
Targets
MOR (Mu opioid receptor)Shigella spp. (Shigella species)
Beyond the preview
Go deeper on lactobacillus acidophilus NCFM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus NCFM.